1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data

 
• By Kevin Grogan

Clinicians and the company have heralded the IMpassion130 data presented at ESMO which showed that Roche's Tecentriq is the first immunotherapy to improve outcomes in TNBC but a slight blot on the landscape is that pretty much all of the survival benefit was seen in breast cancer patients with PD-L1 positive tumors.

two couple are showing half full and half empty side of water glass with their fingers
Roche is taking a glass-half-full attitude to IMpassion130 data • Source: Shutterstock

The excitement surrounding Roche's PD-L1 checkpoint inhibitor Tecentriq (atezolizumab) as a potential treatment for triple-negative breast cancer (TNBC) has subsided just a little despite promising data presented at ESMO from the Swiss group's closely watched IMpassion130 trial.

The late-breaking results from the study reported at the congress in Munich showed that a combination of Tecentriq and Celgene Corp.'s chemotherapy Abraxane (nab-paclitaxel) reduced the risk of disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas